Odylia CEO, Scott Dorfman, speaks at NIH/FDA Gene Therapy Manufacturing meeting

Odylia founder and CEO, Scott Dorfman, recently spoke at the The National Institutes of Health and FDA Workshop on Expanding AAV Manufacturing Capacity for Rare Disease Gene Therapies. In the link included, you can listen to Scott discuss converting silo’ed, ‘vertical’ information in specialized organizations into ‘horizontal’ solutions for all members of the rare disease community. Odylia continues to make strides towards ensuring gene therapy is available for rare diseases, and this presentation highlights the ways manufacturing can support this effort.